Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent

Martin H Bernardi, Harald Rinoesl, Klaus Dragosits, Robin Ristl, Friedrich Hoffelner, Philipp Opfermann, Christian Lamm, Falk Preißing, Dominik Wiedemann, Michael J Hiesmayr, Andreas Spittler, Martin H Bernardi, Harald Rinoesl, Klaus Dragosits, Robin Ristl, Friedrich Hoffelner, Philipp Opfermann, Christian Lamm, Falk Preißing, Dominik Wiedemann, Michael J Hiesmayr, Andreas Spittler

Abstract

Background: Cardiopulmonary bypass (CPB) surgery initiates a systemic inflammatory response, which is associated with postoperative morbidity and mortality. Hemoadsorption (HA) of cytokines may suppress inflammatory responses and improve outcomes. We tested a new sorbent used for HA (CytoSorb™; CytoSorbents Europe GmbH, Berlin, Germany) installed in the CPB circuit on changes of pro- and anti-inflammatory cytokines levels, inflammation markers, and differences in patients' perioperative course.

Methods: In this first pilot trial, 37 blinded patients were undergoing elective CPB surgery at the Medical University of Vienna and were randomly assigned to HA (n = 19) or control group (n = 18). The primary outcome was differences of cytokine levels (IL-1β, IL-6, IL-18, TNF-α, and IL-10) within the first five postoperative days. We also analyzed whether we can observe any differences in ex vivo lipopolysaccharide (LPS)-induced TNF-α production, a reduction of high-mobility box group 1 (HMGB1), or other inflammatory markers. Additionally, measurements for fluid components, blood products, catecholamine treatment, bioelectrical impedance analysis (BIA), and 30-day mortality were analyzed.

Results: We did not find differences in our primary outcome immediately following the HA treatment, although we observed differences for IL-10 24 hours after CPB (HA: median 0.3, interquartile range (IQR) 0-4.5; control: not traceable, P = 0.0347) and 48 hours after CPB (median 0, IQR 0-1.2 versus not traceable, P = 0.0185). We did not find any differences for IL-6 between both groups, and other cytokines were rarely expressed. We found differences in pretreatment levels of HMGB1 (HA: median 0, IQR 0-28.1; control: median 48.6, IQR 12.7-597.3, P = 0.02083) but no significant changes to post-treatment levels. No differences in inflammatory markers, fluid administration, blood substitution, catecholamines, BIA, or 30-day mortality were found.

Conclusions: We did not find any reduction of the pro-inflammatory response in our patients and therefore no changes in their perioperative course. However, IL-10 showed a longer-lasting anti-inflammatory effect. The clinical impact of prolonged IL-10 needs further evaluation. We also observed strong inter-individual differences in cytokine levels; therefore, patients with an exaggerated inflammatory response to CPB need to be identified. The implementation of HA during CPB was feasible.

Trial registration: ClinicalTrials.gov: NCT01879176, registration date: June 7, 2013.

Keywords: Cardiac surgery; Cardiopulmonary bypass; CytoSorb; Cytokine storm; Cytokines; Hemadsorption; High-mobility box group 1; Inflammation; Interleukin.

Figures

Fig. 1
Fig. 1
The selection process for patients included in the study
Fig. 2
Fig. 2
Comparison of median cytokine levels in picograms per milliliter. Red lines indicate the patients in the CytoSorb™ treatment group. Black lines indicate the patients in the control group. Error bars correspond to interquartile ranges (first quartile, third quartile). Asterisks mark differences between both groups at a significance P < 0.05
Fig. 3
Fig. 3
Exponential decay model for mean interleukin-10 (IL-10). Black circles indicate IL-10 values for the control group, and red squares indicate IL-10 values for the CytoSorb™ group

References

    1. Tomic V, Russwurm S, Moller E, Claus RA, Blaess M, Brunkhorst F, et al. Transcriptomic and proteomic patterns of systemic inflammation in on-pump and off-pump coronary artery bypass grafting. Circulation. 2005;112:2912–2920.
    1. Diegeler A, Doll N, Rauch T, Haberer D, Walther T, Falk V, et al. Humoral immune response during coronary artery bypass grafting: A comparison of limited approach, “off-pump” technique, and conventional cardiopulmonary bypass. Circulation. 2000;102(19 Suppl 3):III95–III100.
    1. Chew MS, Brandslund I, Brix-Christensen V, Ravn HB, Hjortdal VE, Pedersen J, et al. Tissue injury and the inflammatory response to pediatric cardiac surgery with cardiopulmonary bypass: a descriptive study. Anesthesiology. 2001;94:745–753. doi: 10.1097/00000542-200105000-00010.
    1. de Jong PR, Schadenberg AW, van den Broek T, Beekman JM, van Wijk F, Coffer PJ, et al. STAT3 regulates monocyte TNF-alpha production in systemic inflammation caused by cardiac surgery with cardiopulmonary bypass. PLoS One. 2012;7:e35070. doi: 10.1371/journal.pone.0035070.
    1. Shen X, Li WQ. High-mobility group box 1 protein and its role in severe acute pancreatitis. World J Gastroenterol. 2015;21:1424–1435. doi: 10.3748/wjg.v21.i5.1424.
    1. Seghaye M, Duchateau J, Bruniaux J, Demontoux S, Bosson C, Serraf A, et al. Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations. J Thorac Cardiovasc Surg. 1996;111:545–553. doi: 10.1016/S0022-5223(96)70306-9.
    1. Sablotzki A, Welters I, Lehmann N, Menges T, Gorlach G, Dehne M, et al. Plasma levels of immunoinhibitory cytokines interleukin-10 and transforming growth factor-beta in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg. 1997;11:763–768. doi: 10.1016/S1010-7940(97)01154-8.
    1. Tarnok A, Schneider P. Pediatric cardiac surgery with cardiopulmonary bypass: pathways contributing to transient systemic immune suppression. Shock. 2001;16(Suppl 1):24–32. doi: 10.1097/00024382-200116001-00006.
    1. Franke A, Lante W, Fackeldey V, Becker HP, Thode C, Kuhlmann WD, et al. Proinflammatory and antiinflammatory cytokines after cardiac operation: different cellular sources at different times. Ann Thorac Surg. 2002;74:363–370. doi: 10.1016/S0003-4975(02)03658-5.
    1. Exner R, Tamandl D, Goetzinger P, Mittlboeck M, Fuegger R, Sautner T, et al. Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide-stimulated tumor necrosis factor-alpha response. Ann Surg. 2003;237:110–115. doi: 10.1097/00000658-200301000-00015.
    1. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:1243–1253. doi: 10.1016/S0140-6736(15)00273-1.
    1. Basu R, Pathak S, Goyal J, Chaudhry R, Goel RB, Barwal A. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: a case study. Indian J Crit Care Med. 2014;18:822–824. doi: 10.4103/0972-5229.146321.
    1. Society of Thoracic Surgeons Blood Conservation Guideline Task F. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944–982. doi: 10.1016/j.athoracsur.2010.11.078.
    1. Society of Thoracic Surgeons Blood Conservation Guideline Task F. Ferraris VA, Ferraris SP, Saha SP, Hessel EA, 2nd, Haan CK, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(5):S27–S86. doi: 10.1016/j.athoracsur.2007.02.099.
    1. Kushner RF, Schoeller DA. Estimation of total body water by bioelectrical impedance analysis. Am J Clin Nutr. 1986;44:417–424.
    1. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, et al. Bioelectrical impedance analysis--part I: review of principles and methods. Clin Nutr. 2004;23:1226–1243. doi: 10.1016/j.clnu.2004.06.004.
    1. Nebelsiek T, Beiras-Fernandez A, Kilger E, Mohnle P, Weis F. Routine use of corticosteroids to prevent inflammation response in cardiac surgery. Recent Pat Cardiovasc Drug Discov. 2012;7:170–174. doi: 10.2174/157489012803832829.
    1. Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg. 2005;3:129–140. doi: 10.1016/j.ijsu.2005.04.002.
    1. Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008;36:268–272. doi: 10.1097/.
    1. Song M, Winchester J, Albright RL, Capponi VJ, Choquette MD, Kellum JA. Cytokine removal with a novel adsorbent polymer. Blood Purif. 2004;22:428–434. doi: 10.1159/000080235.
    1. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med. 2004;32:801–805. doi: 10.1097/01.CCM.0000114997.39857.69.
    1. Pattnaik SK, Panda B. CytoSorb-friend or foe!! Indian J Crit Care Med. 2015;19:296. doi: 10.4103/0972-5229.156504.
    1. Bruenger F, Kizner L, Weile J, Morshuis M, Gummert JF. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs. 2015;38:113–116. doi: 10.5301/ijao.5000382.
    1. Vocelka CR, Jones KM, Mikhova KM, Ebisu RM, Shar A, Kellum JA, et al. Role of cytokine hemoadsorption in cardiopulmonary bypass-induced ventricular dysfunction in a porcine model. J Extra Corpor Technol. 2013;45:220–227.
    1. Bernardi MH, Schmidlin D, Schiferer A, Ristl R, Neugebauer T, Hiesmayr M, et al. Impact of preoperative serum creatinine on short- and long-term mortality after cardiac surgery: a cohort study. Br J Anaesth. 2015;114:53–62. doi: 10.1093/bja/aeu316.
    1. Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, et al. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth. 2009;23:223–231. doi: 10.1053/j.jvca.2008.08.007.
    1. Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, et al. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial. Crit Care Med. 1998;26:1650–1659. doi: 10.1097/00003246-199810000-00016.
    1. Zhang WR, Garg AX, Coca SG, Devereaux PJ, Eikelboom J, Kavsak P, et al. Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. J Am Soc Nephrol. 2015;26:3123–3132. doi: 10.1681/ASN.2014080764.
    1. Frasnelli SC, de Medeiros MC, Bastos Ade S, Costa DL, Orrico SR, Rossa JC. Modulation of immune response by RAGE and TLR4 signalling in PBMCs of diabetic and non-diabetic patients. Scand J Immunol. 2015;81:66–71. doi: 10.1111/sji.12241.
    1. Tanaka Y. Immunosuppressive mechanisms in diabetes mellitus. Nippon Rinsho. 2008;66:2233–2237.
    1. Koh GC, Peacock SJ, van der Poll T, Wiersinga WJ. The impact of diabetes on the pathogenesis of sepsis. Eur J Clin Microbiol Infect Dis. 2012;31:379–388. doi: 10.1007/s10096-011-1337-4.
    1. Wang N, Min X, Li D, He P, Zhao L. Geranylgeranylacetone protects against myocardial ischemia and reperfusion injury by inhibiting high-mobility group box 1 protein in rats. Mol Med Rep. 2012;5:521–524.
    1. Gratia S, Kay L, Potenza L, Seffouh A, Novel-Chate V, Schnebelen C, et al. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Cardiovasc Res. 2012;95:290–299. doi: 10.1093/cvr/cvs134.
    1. Bangert A, Andrassy M, Muller AM, Bockstahler M, Fischer A, Volz CH, et al. Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci U S A. 2016;113:E155–E164. doi: 10.1073/pnas.1522288113.
    1. Asavarut P, Zhao H, Gu J, Ma D. The role of HMGB1 in inflammation-mediated organ injury. Acta Anaesthesiol Taiwan. 2013;51:28–33. doi: 10.1016/j.aat.2013.03.007.
    1. O’Neal HR, Jr, Koyama T, Koehler EA, Siew E, Curtis BR, Fremont RD, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med. 2011;39:1343–1350. doi: 10.1097/CCM.0b013e3182120992.
    1. Landis RC, Brown JR, Fitzgerald D, Likosky DS, Shore-Lesserson L, Baker RA, et al. Attenuating the Systemic Inflammatory Response to Adult Cardiopulmonary Bypass: A Critical Review of the Evidence Base. J Extra Corpor Technol. 2014;46:197–211.
    1. Paparella D, Micelli M, Favoino B, D’Alo M, Fiore T, de Luca Tupputi Schinosa L. Anti-heparin-platelet factor 4 antibodies after cardiopulmonary bypass: role of HLA expression. Haematologica. 2001;86:326–327.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe